[ad_1]
\n<\/p>\n
The arrival of rapid diagnostic test (RDT) kits for cholera in Malawi today signals the start of a global programme that will see more than 1.2 million tests distributed to 14 countries at high risk for cholera over the next several months. Countries that will receive kits in the coming weeks in this largest-ever global deployment include those currently severely impacted by cholera outbreaks, such as Ethiopia, Somalia, Syria, and Zambia. This programme will improve the timeliness and accuracy of outbreak detection and response by boosting routine surveillance and testing capacity and helping rapidly identify probable cholera cases. Critically, it will also help countries monitor trends and build an evidence base for future preventive programmes, supporting the achievement of national cholera control and elimination targets.\u00a0 <\/p>\n
The global cholera diagnostics programme is funded and coordinated by Gavi, the Vaccine Alliance<\/a> (Gavi), with procurement and delivery to countries led by UNICEF<\/a>, and undertaken in collaboration with the Global Task Force on Cholera Control (GTFCC), and WHO<\/a>. It was developed in partnership with FIND<\/a>, who led development of a target product profile describing the required characteristics of cholera RDTs, and other organizations.\u00a0These initial shipments signal the start of the programme, which aims to see partners deploy RDTs to additional countries that have expressed interest in the future. Long-term sustainability of the programme depends on successful fundraising for Gavi\u2019s next strategic period, from 2026 to 2030. <\/p>\n Through this effort, rapid diagnostic tests from two manufacturers \u2013 that have to-date been supplied via WHO and UNICEF for use in outbreak response \u2013 will now be used routinely for cholera surveillance. Pilot studies across the Democratic Republic of the Congo (DRC), Niger and Nepal, funded by Gavi and led by the United States Centers for Disease Control and Prevention (CDC), Johns Hopkins University (JHU) and Epicentre\/ M\u00e9decins Sans Fronti\u00e8res have helped increase understanding of effective rapid testing strategies. Preliminary insights from these studies, which are still ongoing, have helped inform programme design \u2013 making the rollout of these tests at scale more effective. <\/p>\n Cholera has been surging globally since 2021, with high case fatality rates despite availability of simple, effective and affordable treatment. The large number of outbreaks has led to unprecedented demand for vaccines from impacted countries. While global oral cholera vaccine supply has increased eighteen-fold between 2013 and 2023, the large and sustained spike in demand compared to the current availability has put a strain on the global stockpile. Preventive vaccination campaigns have had to be delayed to preserve doses for emergency outbreak response efforts. Recurring outbreaks in countries where emergency vaccination campaigns have already been implemented further highlight the need for improved speed and accuracy in identifying areas with new or persistent transmission \u2013 enabling these areas to be targeted during initial outbreak response efforts. <\/p>\n In 2021, the Gavi Board approved US$ 55 million in funding to support a diagnostics programme between 2022 and- 2025 across cholera, yellow fever, measles, rubella, meningococcal meningitis and typhoid\u00a0 \u2013 with the aim to improve disease surveillance, outbreak detection and response and the design of preventive programmes. Gavi then opened a cholera diagnostics application window in June 2023 \u2013 which is still open \u2013 and so far 14 countries have submitted applications and been approved by an Independent Review Committee of experts. In 2023, Gavi also launched a preventive cholera vaccination programme, to support countries with long-term cholera control \u2013 a strategy that has successfully led to a decrease in outbreaks of diseases such as yellow fever and meningitis. \u00a0\u00a0<\/p>\n Cholera is an acute intestinal infection that spreads through food and water contaminated with faeces containing the bacterium Vibrio cholerae<\/em>.\u00a0\u00a0The rise in cholera is driven by continued gaps in access to safe water and sanitation, and failure to quickly detect outbreaks and limit their spread. The communities impacted often do not have access to basic health services, a situation made worse by climate-related factors, conflict and population displacement.\u00a0In the face of the ongoing surge, partners working on cholera control have urgently called on countries, manufacturers and other partners to invest in the timely outbreak response and case management, rapid access to treatment, increased production of affordable vaccines, and urgent improvements in access to basic water and sanitation services in impacted communities.<\/p>\n To be effective, these multisectoral strategies for the control of cholera must be guided by timely and reliable cholera surveillance data. Surveillance not only supports the early detection of and quick response to an outbreak, but also plays a central role in providing stakeholders in other cholera prevention and control pillars with the data they need to target, design, implement, and evaluate interventions. In 2023, the GTFCC updated recommendations in favor of strategic, routine and systematic testing of suspected cholera cases and the expanded use of RDTs to strengthen cholera surveillance. The global cholera RDT procurement program provides the additional support required for eligible countries to implement these recommendations.\u00a0 <\/p>\n \u201cWe are experiencing an unprecedented multi-year upsurge in cholera cases worldwide, and today\u2019s announcement provides a critical boost in the fight against the disease. The rise in infections is being driven by continued gaps in access to safe water and sanitation, and our inability to reach vulnerable communities that are being put further at risk by climate change, conflict and displacement,\u201d said Aur\u00e9lia<\/strong> Nguyen<\/strong>, Chief Programme Officer at Gavi, the Vaccine Alliance.<\/strong> \u201cRoutine use of diagnostics will bolster cholera surveillance in impacted countries, and must be leveraged to better target vaccination efforts, which play a critical role in multisectoral cholera prevention and control programmes.\u201d <\/p>\n \u201cDespite cholera being preventable and easily treatable, children continue to suffer from this potentially fatal disease. This is why we are working with partners on all fronts and in novel ways to stem outbreaks,\u201d said Leila Pakkala, Director of UNICEF Supply Division<\/strong>.<\/strong> \u201cSurveillance diagnostics help pinpoint hotspots with great precision. This allows partners to target cholera vaccines to exactly the time and place where the limited supply will save the most lives.\u201d<\/p>\n \u201cIt\u2019s a tragedy that cholera\u2014a preventable and treatable disease\u2014continues to afflict and kill today. We need urgent action on all fronts, including commitment by countries to clean water, sanitation and hygiene,\u201d said Dr Michael Ryan, Executive Director of WHO\u2019s Health Emergencies Programme<\/strong>. \u201cWHO welcomes the deployment of these rapid cholera tests. They will equip health workers with the critical and timely data needed to stop outbreaks early and direct efforts to better prevent and treat cholera.\u201d <\/p>\n \u201cCholera is now spreading to areas that have been free from the disease for many years, demanding a swift, multifaceted strategy to direct limited resources to critical areas and save lives. Accurate and high-quality testing and surveillance measures are vital to spot the disease where it is emerging, confirm cholera cases amidst other diarrheal illnesses, and evaluate the success of preventative measures such as vaccines,\u201d said Dr Sergio Carmona, Acting CEO and Chief Medical Officer at FIND<\/strong>.<\/p>\n <\/p>\n Gavi<\/strong><\/p>\n UNICEF<\/strong><\/p>\n FIND<\/strong>
\n<\/p>\n About Gavi<\/strong><\/p>\n Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world\u2019s children against some of the world\u2019s deadliest diseases. The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill & Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organisations that fund Gavi\u2019s work\u00a0 here<\/a>.<\/p>\n Since its inception in 2000, Gavi has helped to immunise a whole generation \u2013 over 1 billion children \u2013 and prevented more than 17.3 million future deaths, helping to halve child mortality in 78 lower-income countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningococcal and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation, above all the zero-dose children who have not received even a single vaccine shot. The Vaccine Alliance employs innovative finance and the latest technology \u2013 from drones to biometrics \u2013 to save lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency.<\/p>\n About UNICEF<\/strong><\/p>\n UNICEF works in some of the world\u2019s toughest places, to reach the world\u2019s most disadvantaged children. Across 190 countries and territories, we work for every child, everywhere, to build a better world for everyone. For more information about UNICEF and its work for children, visit www.unicef.org<\/a>. Find out more about UNICEF\u2019s work on the COVID-19 vaccines here<\/a>, or about UNICEF\u2019s work on immunization here<\/a>.<\/p>\n About WHO<\/strong> Dedicated to the well-being of all people and guided by science, the World Health Organization leads and champions global efforts to give everyone, everywhere an equal chance at a safe and healthy life. We are the UN agency for health that connects nations, partners and people on the front lines in 150+ locations \u2013 leading the world\u2019s response to health emergencies, preventing disease, addressing the root causes of health issues and expanding access to medicines and health care. Our mission is to promote health, keep the world safe and serve the vulnerable. www.who.int<\/a> \u00a0\u00a0<\/p>\n About FIND<\/strong><\/p>\n FIND accelerates equitable access to reliable diagnosis around the world. We are working to close critical testing gaps that leave people at risk from preventable and treatable illnesses, enable effective disease surveillance, and build sustainable, resilient health systems. In partnership with countries, WHO and other global health agencies, we are driving progress towards global health security and universal health coverage. We are a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation. For more information, please visit www.finddx.org<\/a>.<\/p>\n \u00a0<\/p>\n \u00a0<\/p>\n<\/div>\nNote to editors<\/h3>\n
\n